DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
04/27/2023* -- Results Q1 2023 -- 0.46 --
04/27/2023* 13:30 EST Earnings Call Q1 2023 -- -- --
02/27/2023 -- Results Q4 2022 0.36 0.39 -7.10%
02/27/2023 16:30 EST Earnings Call Q4 2022 -- -- --
10/26/2022 -- Results Q3 2022 0.45 0.43 4.85%
10/26/2022 16:30 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 0.58 0.53 9.49%
08/03/2022 16:30 EST Earnings Call Q2 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 04/27/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 02/27/2023
Beat/Miss Upgrade
Return Since -11.37%
Last FQE 12/31/2022
Next FQE 03/31/2023

Profile

Edit
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and is poised for U.S. approval in 2023.
URL http://www.bmrn.com
Investor Relations URL https://investors.biomarin.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Apr. 27, 2023 (est.)
Last Earnings Release Feb. 27, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Annual Total Returns Versus Peers

Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
-20.92%
7.64%
-4.51%
-0.70%
3.71%
0.75%
17.14%
-11.59%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
4.03%
--
--
--
--
102.9%
-76.54%
-54.32%
87.93%
-60.23%
239.3%
-42.61%
57.96%
12.85%
30.48%
40.14%
-19.84%
-28.90%
102.8%
96.14%
18.24%
32.12%
-47.18%
43.90%
1.20%
--
-5.41%
-67.64%
4.75%
186.0%
69.64%
-68.10%
99.45%
As of March 27, 2023.

Profile

Edit
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and is poised for U.S. approval in 2023.
URL http://www.bmrn.com
Investor Relations URL https://investors.biomarin.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Apr. 27, 2023 (est.)
Last Earnings Release Feb. 27, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PBE 11.05M USD 4.49%
VHCOX 599.57M USD 3.27%
POAGX 198.35M USD 3.08%
BBH 15.08M USD 3.08%
POGRX 173.46M USD 2.62%
BMEZ 36.36M USD 1.83%
IBB 127.97M USD 1.61%
VAFNX 155.43M USD 1.42%
SCHM 44.53M USD 0.49%
FSMAX 109.71M USD 0.33%
VEXMX 252.52M USD 0.29%
VXF 252.52M USD 0.29%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BMRN Tweets